Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
Structure Therapeutics (NASDAQ: GPCR) management will participate in the Jefferies Global Healthcare Conference in London on November 17, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Structure Therapeutics (NASDAQ: GPCR) management will participate in the Jefferies Global Healthcare Conference in London on November 17, 2026. The scheduled format includes a fireside chat and one-on-one meetings at 12:00 PM GMT. Live and archived webcasts will be accessible through the company’s website, with replays available for at least 90 days.
Details
News Market Reaction – GPCR
On Nov 4, the day this news came out, GPCR closed 0.05% above the previous close. Our momentum scanner recorded 7 alerts for this stock that day.
Data tracked by StockTitan Argus for the Nov 4 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced that management will participate in the Jefferies Global Healthcare Conference being held November 16-19, 2026 in London, UK.
Jefferies Global Healthcare Conference
Date: Tuesday, November 17
Format: Fireside chat and 1x1 meetings
Time: 12:00 PM GMT
Location: London, UK
The live and archived webcasts will be accessible from the company’s website at https://ir.structuretx.com/events-presentations/events and replays will be available for at least 90 days.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com
Jennifer Robinson
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
